Table 5.
Total PG | Studied PG | Survival-Related PG | Signature-PG |
---|---|---|---|
14,126 | 1333 | 125 | 4 |
3Y-AUC | 5Y-AUC | 8Y-AUC | KM-P-value |
Whole patients | |||
0.885 | 0.878 | 0.796 | <0.0001 |
Gender subgroup (male) | |||
0.82 | 0.828 | 0.707 | 0.0064 |
Gender subgroup (female) | |||
0.965 | 0.947 | 0.947 | <0.0001 |
Age subgroup (<18) | |||
0.902 | 0.888 | 0.788 | <0.0001 |
Age subgroup (≥18) | |||
0.828 | 0.861 | 0.796 | 0.038 |
Metastatic subgroup (non-meta) | |||
0.871 | 0.87 | 0.743 | 0.00014 |
Metastatic subgroup (meta) | |||
0.91 | 0.89 | 0.89 | <0.0001 |
Gene signature | |||
0.821 | 0.861 | 0.781 | <0.0001 |
Combined signature | |||
0.937 | 0.956 | 0.871 | <0.0001 |
PG: pseudogene; Y: year.